Vertex Pharmaceuticals (VRTX)

• Market cap: $102B
• 1 day: 0.16%
• 5 days: -14.27%
• 1 month: -11.96%
• 3 months: -14.55%
• 6 months: -15.72%
• Year to date: -3.32%
• 1 year: -0.74%
• 5 years: 80.01%
• 10 years: 240.48%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Employees: 5,400

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

22% more call options, than puts

Call options by funds: $881M | Put options by funds: $721M

8% more repeat investments, than reductions

Existing positions increased: 616 | Existing positions reduced: 572

1% less funds holding

Funds holding: 1,527 [Q2] → 1,516 (-11) [Q3]

4% less capital invested

Capital invested by funds: $111B [Q2] → $107B (-$3.92B) [Q3]

9% less first-time investments, than exits

New positions opened: 117 | Existing positions closed: 128

2.65% less ownership

Funds ownership: 92.33% [Q2] → 89.67% (-2.65%) [Q3]

9% less funds holding in top 10

Funds holding in top 10: 32 [Q2] → 29 (-3) [Q3]

Research analyst outlook

15 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $408 3% upside
• Avg. target: $503 27% upside
• High target: $586 48% upside

15 analyst ratings

• positive: 9 60%
• neutral: 5 33%
• negative: 1 7%

Barclays Gena Wang 13% 1-year accuracy 4 / 30 met price target	5% upside $418	Equal-Weight Maintained	20 Dec 2024
BMO Capital Evan Seigerman 50% 1-year accuracy 8 / 16 met price target	31% upside $520	Outperform Maintained	20 Dec 2024
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 105 / 327 met price target	35% upside $535	Buy Maintained	20 Dec 2024
B of A Securities Ying Huang 50% 1-year accuracy 1 / 2 met price target	31% upside $522	Buy Maintained	19 Dec 2024
Stifel Paul Matteis 13% 1-year accuracy 2 / 15 met price target	24% upside $494	Hold Maintained	16 Dec 2024